Hologic (HOLX) Aktsia Kursus
Hologic Kursus
Viimase 19 aasta jooksul kasvas Hologic käive 12,2 % aastas ja jõudis 4,10 B USD-ni. Kasum aktsia kohta kasvas 12,8 % aastas viimase 19 aasta jooksul. Hologic netomarginaal 13,8 % on langenud võrreldes 33,2 %-ga mõni aasta tagasi. Hologic 12 kuu konsensuse hinnasiht on 77,52 USD, umbes üle kurssi 2,0 %. 23 analüütikust 0 soovitab osta — üldine konsensus on Hoia.
Hologic aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Hologic ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Hologic aktsia kohta
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
The business model of Hologic Inc revolves around providing innovative diagnostic solutions, primarily focused on women's healthcare. Hologic develops and markets a wide range of medical devices and instruments, including imaging systems, surgical products, and molecular diagnostic assays. The company's products are designed to enable healthcare professionals to effectively screen, diagnose, and treat various conditions and diseases. Hologic is renowned for its advanced technologies in breast health, gynecology, and skeletal health, offering solutions that empower early detection and intervention. By constantly pushing the boundaries of medical technology, Hologic Inc remains committed to improving healthcare outcomes for women around the world.
Hologic Inc is primarily active in the healthcare industry, specifically in the field of diagnostic products and medical devices. With a focus on improving women's health, Hologic Inc develops and manufactures a wide range of innovative solutions. Their portfolio includes advanced imaging systems, molecular diagnostic assays, surgical instruments, and women's health screening tests. As a prominent player in the healthcare sector, Hologic Inc constantly strives to provide cutting-edge technologies and solutions to address various medical challenges.
Hologic Inc is a leading global healthcare and diagnostics company. Established in 1985, Hologic has excelled in providing innovative solutions for women's health, with a focus on early detection and treatment of breast and cervical cancers. The company's dedication to research and development has resulted in breakthrough technologies, including the introduction of the first 3D mammography system. Hologic has expanded its portfolio to include diagnostics, surgical and skeletal health, and GYN surgical products. With a strong commitment to advancing healthcare, Hologic Inc continues to make significant contributions to improving patient outcomes and quality of life.
Hologic Inc, a leading healthcare company, has achieved several significant milestones. In recent years, the company has made notable advancements in breast health solutions. They introduced the world's first 3D mammography system, which revolutionized breast cancer detection by providing clearer and more accurate images. Hologic Inc also developed the Genius™ 3D Mammography™ exam, proven to detect breast cancer at an earlier stage compared to 2D mammography alone. Furthermore, the company expanded its portfolio by acquiring Gen-Probe, a molecular diagnostics company, allowing Hologic Inc to offer a comprehensive range of diagnostic solutions. These milestones highlight Hologic Inc's commitment to innovation and improving women's healthcare outcomes.
Hologic Inc is primarily present in various countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Hologic Inc operates in Europe, including countries like Germany, France, Italy, and the United Kingdom. It also has a presence in Asia, particularly in countries such as China and Japan. Furthermore, Hologic Inc serves customers in Canada and Latin America, with a focus on countries like Mexico and Brazil. Overall, Hologic Inc has a global reach and aims to provide its products and services to diverse markets internationally.
Hologic Inc represents values of innovation, commitment to quality, and patient-centric approach. The corporate philosophy of Hologic Inc revolves around developing cutting-edge medical technologies to improve women's health outcomes. With a focus on providing accurate and reliable diagnostic solutions, Hologic Inc strives to empower healthcare professionals and patients alike. The company's dedication to research and development, evidence-based practices, and collaboration with healthcare experts reinforces its commitment to advancing healthcare for women globally. Hologic Inc's mission is to make a difference in people's lives through advanced healthcare solutions, making them a trusted and reliable leader in the industry.
Analüütikud määravad Hologic aktsiale keskmiseks hinnasihi 76,66 USD (mediaan: 77,52 USD), mis on +0,9 % viimase hinna suhtes. Konsensus põhineb 23 analüütiku hinnangul.
23 analüütikut hindavad praegu Hologic aktsiat: 0 soovitab osta, 20 hoida ja 3 müüa. 2026. aastaks ootavad analüütikud, et Hologic teenib tulu 4,24 B USD ja kasumit aktsia kohta 4,49 USD.
Praeguse kursiga kaubeldakse Hologic aktsiaga 67,95 EUR (76,01 USD) juures.
Hologic aktsia (HOLX) on noteeritud 9 börsil, sh: NASDAQ (HOLX), London (0J5Q.L), SIX (Zürich) (HO1.SW), XETRA (HO1.DE), Frankfurt (HO1.F), München (HO1.MU), Düsseldorf (HO1.DU), Wien (HOLX.VI).
Hologic Inc is an international leading provider of medical technology products and solutions. The company, headquartered in Marlborough, Massachusetts, operates globally and is divided into four business segments: Diagnostics, Gynecology, Skeletal Health, and Aesthetics.
oodatav Hologic käive on 4,24 B USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Hologic kasum on 1,01 B USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Hologic jaoks on praegu 16,93. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Hologic aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Hologic jaoks on praegu 4,05. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Hologic aktsia jaoks.
Eulpooli kvaliteedinäitaja Hologic jaoks on 1/10.
Hologic ISIN on US4364401012. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Hologic WKN on 879100. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Hologic ticker on HOLX. Ticker-sümbol kasutatakse Hologic aktsiate kauplemiseks börsil.
Hologic aktsia
Hologic konkurendid
Hologic Börsiticker
Hologic FIGI
Kõik teised näitajad ja analüüsid Hologic kohta sügavamalt
Meie Hologic-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Hologic. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: